Showing results (1031-1040 of 5,983) with videos related to

Sort By:
Pageof 599
Molecular Cancer Therapeutics|April 3, 2012
Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactionsRona Ortenberg, Yair Sapir, Lee Raz, et al.
Molecular Cancer Therapeutics|April 17, 2012
Preclinical analysis of the γ-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemiaJeremy B Samon, Mireia Castillo-Martin, Michael Hadler, et al.
Molecular Cancer Therapeutics|April 13, 2012
Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implicationsJuan Carlos Montero, Xi Chen, Alberto Ocaña, et al.
Molecular Cancer Therapeutics|April 5, 2012
Adenosine A2A and beta-2 adrenergic receptor agonists: novel selective and synergistic multiple myeloma targets discovered through systematic combination screeningRichard J Rickles, Winnie F Tam, Thomas P Giordano, et al.
Molecular Cancer Therapeutics|April 27, 2011
Cancer cells cyclically lose and regain drug-resistant highly tumorigenic features characteristic of a cancer stem-like phenotypeKaijie He, Tong Xu, Amir Goldkorn
Molecular Cancer Therapeutics|April 27, 2011
Targeted nanogels: a versatile platform for drug delivery to tumorsEric A Murphy, Bharat K Majeti, Rajesh Mukthavaram, et al.
Molecular Cancer Therapeutics|November 4, 2010
Chemopreventive effects of pioglitazone on chemically induced lung carcinogenesis in miceYian Wang, Michael James, Weidong Wen, et al.
Molecular Cancer Therapeutics|November 4, 2010
Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser¹⁰ p27 phosphorylation in epidermal growth factor receptor-expressing breast cancerDongwei Zhang, Ana M Tari, Ugur Akar, et al.
Molecular Cancer Therapeutics|May 14, 2011
Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagyAshutosh Shrivastava, Paula M Kuzontkoski, Jerome E Groopman, et al.
Molecular Cancer Therapeutics|June 18, 2011
Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approachJanice M Mehnert, Antoinette R Tan, Rebecca Moss, et al.
Pageof 599